UDX also announces the initial closing of its series B financing of approximately $70 million with investors, including Quest Diagnostics
Financing to support UDX’s pursuit of FDA premarket approval for its colorectal cancer screening blood test
i Quest Diagnostics Incorporated logo. (PRNewsFoto/Quest Diagnostics Incorporated) Under the commercial agreement between UDX and Quest, Quest plans to perform and provide clinical laboratory services to providers and patients in the United States based on UDX’s Signal-C®, an advanced colorectal cancer screening blood test, assuming premarket approval of the test in the United States.To support a submission to the U.S. Food […]
Click here to visit source. newsroom.questdiagnostics.com